![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
ENS-002 is an investigational live biotherapeutic product (LBP) applied topically, being investigated to treat atopic dermatitis (AD).
Lead Product(s): ENS-002
Therapeutic Area: Dermatology Product Name: ENS-002
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 26, 2024
Details:
The company’s first microbial product, “Ensemble No.2” (ENS-002), is designed to rehabilitate the skin microbiome. By taming the pathogenic behaviors of Staphylococcus aureus, ENS-002 may decrease the frequency and severity of eczema flares.
Lead Product(s): ENS-002
Therapeutic Area: Dermatology Product Name: ENS-002
Highest Development Status: DiscoveryProduct Type: Large molecule
Partner/Sponsor/Collaborator: Safar Partners
Deal Size: $23.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing November 02, 2022